JP7007302B2 - メニン－ｍｌｌ相互作用の阻害剤 - Google Patents

メニン－ｍｌｌ相互作用の阻害剤 Download PDF

Info

Publication number
JP7007302B2
JP7007302B2 JP2018564288A JP2018564288A JP7007302B2 JP 7007302 B2 JP7007302 B2 JP 7007302B2 JP 2018564288 A JP2018564288 A JP 2018564288A JP 2018564288 A JP2018564288 A JP 2018564288A JP 7007302 B2 JP7007302 B2 JP 7007302B2
Authority
JP
Japan
Prior art keywords
methyl
diazaspiro
fluoro
pyrimidine
nonane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517548A (ja
JP2019517548A5 (https=
Inventor
カケーシャン サルバチオン
エー．クレアモン デイビッド
ウェイン ディラード ローレンス
トン チョンクオ
ファン イー
チア ランチー
ディー．ロテスタ スティーブン
マーカス アンドリュー
モラールズ－ラモス エンジェル
ビー．シン スレッシュ
ベンカトラマン シャンカー
ユアン チン
チョン ヤーチュン
チョアン リンハン
ディー．ペアレント スティーブン
エル．ヒューストン トラビス
Original Assignee
ヴァイティー ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァイティー ファーマシューティカルズ，エルエルシー filed Critical ヴァイティー ファーマシューティカルズ，エルエルシー
Publication of JP2019517548A publication Critical patent/JP2019517548A/ja
Publication of JP2019517548A5 publication Critical patent/JP2019517548A5/ja
Priority to JP2022000946A priority Critical patent/JP7461390B2/ja
Application granted granted Critical
Publication of JP7007302B2 publication Critical patent/JP7007302B2/ja
Priority to JP2024000278A priority patent/JP2024045176A/ja
Priority to JP2025083421A priority patent/JP2025113339A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2018564288A 2016-06-10 2017-06-08 メニン－ｍｌｌ相互作用の阻害剤 Active JP7007302B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022000946A JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン－ｍｌｌ相互作用の阻害剤
JP2024000278A JP2024045176A (ja) 2016-06-10 2024-01-04 メニン－ｍｌｌ相互作用の阻害剤
JP2025083421A JP2025113339A (ja) 2016-06-10 2025-05-19 メニン－ｍｌｌ相互作用の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348496P 2016-06-10 2016-06-10
US62/348,496 2016-06-10
PCT/US2017/036506 WO2017214367A1 (en) 2016-06-10 2017-06-08 Inhibitors of the menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000946A Division JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン－ｍｌｌ相互作用の阻害剤

Publications (3)

Publication Number Publication Date
JP2019517548A JP2019517548A (ja) 2019-06-24
JP2019517548A5 JP2019517548A5 (https=) 2020-07-27
JP7007302B2 true JP7007302B2 (ja) 2022-01-24

Family

ID=59325631

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018564288A Active JP7007302B2 (ja) 2016-06-10 2017-06-08 メニン－ｍｌｌ相互作用の阻害剤
JP2022000946A Active JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン－ｍｌｌ相互作用の阻害剤
JP2024000278A Pending JP2024045176A (ja) 2016-06-10 2024-01-04 メニン－ｍｌｌ相互作用の阻害剤
JP2025083421A Pending JP2025113339A (ja) 2016-06-10 2025-05-19 メニン－ｍｌｌ相互作用の阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022000946A Active JP7461390B2 (ja) 2016-06-10 2022-01-06 メニン－ｍｌｌ相互作用の阻害剤
JP2024000278A Pending JP2024045176A (ja) 2016-06-10 2024-01-04 メニン－ｍｌｌ相互作用の阻害剤
JP2025083421A Pending JP2025113339A (ja) 2016-06-10 2025-05-19 メニン－ｍｌｌ相互作用の阻害剤

Country Status (21)

Country Link
US (4) US10683302B2 (https=)
EP (2) EP3805215A1 (https=)
JP (4) JP7007302B2 (https=)
KR (3) KR102916887B1 (https=)
CN (1) CN109743875B (https=)
AU (3) AU2017278950B2 (https=)
BR (1) BR122024002146A2 (https=)
CA (2) CA3024180A1 (https=)
CY (1) CY1124834T1 (https=)
DK (1) DK3468966T3 (https=)
ES (1) ES2831084T3 (https=)
HR (1) HRP20201771T1 (https=)
HU (1) HUE051451T2 (https=)
IL (4) IL298381B2 (https=)
LT (1) LT3468966T (https=)
MX (3) MX381228B (https=)
PL (1) PL3468966T3 (https=)
PT (1) PT3468966T (https=)
SI (1) SI3468966T1 (https=)
WO (1) WO2017214367A1 (https=)
ZA (1) ZA201900150B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP4643952A3 (en) 2016-01-26 2026-01-14 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
WO2018190350A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
KR20200101389A (ko) * 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
SG11202101085PA (en) * 2018-08-27 2021-03-30 Sumitomo Dainippon Pharma Co Ltd Optically active azabicyclic derivative
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2020114474A1 (zh) * 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2021060453A1 (ja) 2019-09-27 2021-04-01 大日本住友製薬株式会社 架橋型光学活性２級アミン誘導体
KR20220079921A (ko) 2019-10-09 2022-06-14 노파르티스 아게 M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체
PE20221454A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
JP7454520B2 (ja) * 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
MX2022012471A (es) * 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
WO2022086986A1 (en) * 2020-10-21 2022-04-28 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения
EP4334320A1 (en) * 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
MX2023013436A (es) * 2021-05-11 2023-12-12 Janssen Pharmaceutica Nv Terapias de combinacion.
KR20240006631A (ko) * 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
TW202311262A (zh) * 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
CN117412964A (zh) * 2021-06-03 2024-01-16 首药控股(北京)股份有限公司 取代的杂环化合物及其应用
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
WO2022257047A1 (en) * 2021-06-09 2022-12-15 Acerand Therapeutics (Hong Kong) Limited Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
CA3220099A1 (en) 2021-06-17 2022-12-22 Wei Cai (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
CN113769098B (zh) * 2021-09-22 2022-09-30 中国医学科学院肿瘤医院深圳医院 MLL-menin抑制剂组合物在制备抗肝癌药物中的应用
KR20240144111A (ko) * 2021-12-03 2024-10-02 바이오노바 파마슈티컬스 (상하이) 리미티드 카르보닐 치환된 디아자스피로 화합물 및 이의 용도
KR20240131421A (ko) * 2021-12-31 2024-08-30 히트젠 주식회사 메닌 저해제 및 이의 용도
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
CN117069719A (zh) * 2022-08-17 2023-11-17 烨辉医药科技(上海)有限公司 二氮杂螺环-哒嗪化合物及其用途
TW202415660A (zh) * 2022-09-02 2024-04-16 大陸商和記黃埔醫藥（上海）有限公司 三嗪類化合物及其用途
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN118271341A (zh) * 2022-12-30 2024-07-02 成都先导药物开发股份有限公司 Menin抑制剂及其用途
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN121358726A (zh) * 2023-04-13 2026-01-16 首药控股(北京)股份有限公司 取代的杂环化合物
CN118994033B (zh) * 2023-05-17 2025-09-16 成都先导药物开发股份有限公司 一种sdnx-5613的合成方法及其中间体化合物
CN116969891A (zh) * 2023-07-28 2023-10-31 杭州国瑞生物科技有限公司 一种7-甲基-5-醛基-1h-吲唑的合成方法
TW202525797A (zh) * 2023-08-28 2025-07-01 美商錫達斯醫藥股份有限公司 作為ｍｅｎｉｎ－ｍｌｌ交互作用之抑制劑的芳基醚類似物
WO2025059366A1 (en) * 2023-09-13 2025-03-20 Kumquat Biosciences Inc. Ras inhibitors
TW202527912A (zh) 2023-11-04 2025-07-16 美商欣戴克斯製藥公司 多發性內分泌腺瘤蛋白（ｍｅｎｉｎ）抑制劑的鹽和多晶型形式及其醫藥組成物
WO2025188611A1 (en) * 2024-03-04 2025-09-12 Dana-Farber Cancer Institute, Inc. Chemical matters for targeting leukemic complex proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
JP2016512514A (ja) 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
CN105732636A (zh) 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2018538330A (ja) 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
JP2001270867A (ja) * 2000-03-23 2001-10-02 Sumitomo Chem Co Ltd フェニルピリダジン化合物
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
JP3592301B2 (ja) * 2002-02-07 2004-11-24 株式会社田窪工業所 簡易建造物の床パネルと側面パネルの接続構造
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1732891A4 (en) 2004-03-11 2009-05-06 Sequoia Pharmaceuticals Inc RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
EP2422781A1 (en) 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
US9458124B2 (en) * 2013-02-06 2016-10-04 Wayne State University Substituted pyran derivatives
EP3290407B1 (en) * 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
WO2015108940A2 (en) 2014-01-14 2015-07-23 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors
WO2016025635A2 (en) 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP4643952A3 (en) 2016-01-26 2026-01-14 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
US10899758B2 (en) 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
KR20200101389A (ko) 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP2021519785A (ja) 2018-03-30 2021-08-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン化合物
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
AU2022271791A1 (en) 2021-05-12 2024-01-04 Board Of Regents, The University Of Texas System Combinations for treatment of cancer
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN118234497A (zh) 2021-12-15 2024-06-21 丹娜-法伯癌症研究所 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
JP2016512514A (ja) 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
CN105732636A (zh) 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2018538330A (ja) 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI, Aibin et al.，Structual insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia，Blood，2012年11月29日，vol.120, no.23，pp.4461-4469

Also Published As

Publication number Publication date
KR102916887B1 (ko) 2026-01-22
KR20250079083A (ko) 2025-06-04
AU2021258089B2 (en) 2024-01-25
US20190144459A1 (en) 2019-05-16
ES2831084T3 (es) 2021-06-07
RU2019100040A (ru) 2020-07-13
IL263586B (en) 2021-06-30
US10683302B2 (en) 2020-06-16
HUE051451T2 (hu) 2021-03-01
CY1124834T1 (el) 2022-07-22
IL263586A (en) 2019-01-31
EP3468966B1 (en) 2020-08-05
IL283267A (en) 2021-07-29
JP2019517548A (ja) 2019-06-24
HRP20201771T1 (hr) 2021-02-19
PT3468966T (pt) 2020-11-10
KR20220123727A (ko) 2022-09-08
AU2021258089A1 (en) 2021-11-25
IL298381A (en) 2023-01-01
ZA201900150B (en) 2023-04-26
IL321844A (en) 2025-08-01
BR112018075260A2 (pt) 2019-03-12
US20250326764A1 (en) 2025-10-23
EP3468966A1 (en) 2019-04-17
CN109743875B (zh) 2022-04-29
US11479557B2 (en) 2022-10-25
RU2019100040A3 (https=) 2020-07-15
JP2024045176A (ja) 2024-04-02
CA3024180A1 (en) 2017-12-14
LT3468966T (lt) 2021-02-25
AU2024202700A1 (en) 2024-05-16
WO2017214367A1 (en) 2017-12-14
US20230174541A1 (en) 2023-06-08
MX381228B (es) 2025-03-12
PL3468966T3 (pl) 2021-04-06
IL283267B (en) 2022-12-01
AU2017278950B2 (en) 2021-07-29
IL298381B1 (en) 2025-08-01
BR122024002146A2 (pt) 2024-03-05
JP2025113339A (ja) 2025-08-01
JP2022058514A (ja) 2022-04-12
US12312359B2 (en) 2025-05-27
IL298381B2 (en) 2025-12-01
MX2021003939A (es) 2021-05-27
US20210053974A1 (en) 2021-02-25
EP3805215A1 (en) 2021-04-14
SI3468966T1 (sl) 2021-03-31
CN109743875A (zh) 2019-05-10
MX2018015252A (es) 2019-04-25
AU2017278950A1 (en) 2019-01-03
KR102436430B1 (ko) 2022-08-24
CA3297462A1 (en) 2026-03-02
JP7461390B2 (ja) 2024-04-03
MX2023002982A (es) 2023-04-10
KR20190017012A (ko) 2019-02-19
NZ748203A (en) 2025-06-27
IL283267B2 (en) 2023-04-01
DK3468966T3 (da) 2020-11-09

Similar Documents

Publication Publication Date Title
JP7461390B2 (ja) メニン－ｍｌｌ相互作用の阻害剤
US11739085B2 (en) Inhibitors of the menin-MLL interaction
TW202311262A (zh) Menin-mll交互作用之抑制劑
RU2799820C2 (ru) Ингибиторы взаимодействия менин-mll
RU2829484C2 (ru) Ингибиторы взаимодействия менин-mll
BR112018075260B1 (pt) Compostos inibidores da interação de menina-llm, composição farmacêutica, sal, forma cristalina e uso dos mesmos
HK40007344B (en) Inhibitors of the menin-mll interaction
HK40007344A (en) Inhibitors of the menin-mll interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220106

R150 Certificate of patent or registration of utility model

Ref document number: 7007302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250